CAC2 Childhood Cancer Community News Digest (May 22-28)
Happy Memorial Day!
Assorted News from the Last Week:
Researchers found that the probability of FDA approval within 10 years was 10.4%, but the probability of an investigational cancer drug attaining pediatric approval within 10 years was 1.4%.
Accumulation of chronic disease among childhood cancer survivors predicts early mortality.
In 2006, the Children’s Oncology Group (COG) raised the minimum age at which patients could be assigned as having high-risk neuroblastoma from 12 months to 18 months; those reclassified as intermediate risk under the new schema experienced similar survival outcomes despite the commensurate reduction in therapy.
Upcoming Webinars, Online Opportunities, and Meetings:
Registration has opened for the CAC2 2023 Annual Summit, presented by Day One Biopharmaceuticals! This year’s conference takes place from noon, Monday, June 19 through 2:00 pm, Wednesday, June 21, 2023, in Atlanta, GA, at Children’s Healthcare of Atlanta Emory University. Click here for more information and to register.
MIB Agents Osteosarcoma Alliance FACTOR 2023 Conference brings together the leading osteosarcoma researchers and clinicians, along with patient families and OsteoWarriors (survivors, patients and siblings of OsteoWarriors and OsteoAngels) to Make It Better for those battling this disease. Click here for more information.
Give Kids the World Summer Road Trip! From June 17-26, GKTW visit 10 amusement parks and offer a day of fun for our incredible Alumni families for free. Summer Road Trip info can be found here: https://www.gktw.org/roadtrip/.
Take Action:
Pediatric Cancer legislation needs your support. Learn more about how to support the Gabriella Miller Kids First Research Act 2.0, the Sawyer Finn ACT, and the Give Kids a Chance Act.
The International Agency for Research on Cancer (IARC) and partner institutions are now accepting applications for an online course on the registration of cancer in children. Click here for more information.
Do you have an idea for solving the market failure problem that leads to no or slow drug development for children with cancer? Check out the MSA Innovation Challenge 2023: The submission template asks applicants to identify a market failure where the social value exceeds private incentives and where we know the measurable outcome we want to encourage (e.g. the development of a vaccine, capturing carbon out of the air, etc.). Click here for more information.
SUBSCRIBE
Sign up to receive a copy of CAC2's free childhood cancer news digest in your inbox each week.
Categories
- Blog Posts (97)
- Explainer Post (12)
- Guest Blogs (16)
- Member Blogs (40)
- Survivorship Matters Blog (9)
- CAC2 News (25)
- Collaborative Achievements (14)
- Community News (255)
- In Memoriam (2)
- News Digest (205)
- Webinars (64)